Comparison of the therapeutic effects of intratympanic injections of Triamcinolon and Dexametasone who suffer from sudden sensorineural hearing loss

Phase 3

Recruiting

• Conditions: Sudden sensorineural hearing loss.; Sudden idiopathic hearing loss, bilateral; H91.23

• Registration Number: IRCT20171004036554N4
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 January 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 62

Inclusion Criteria

All patients with SSNH diagnosis who are candidates for intratympanic injection
Patients who have a contraindication to receive systemic corticosteroids, such as underlying diseases like diabetes or defective immune disorders .
Patients who are interested in receiving intra tympanic corticosteroids instead of systemic corticosteroids .

Exclusion Criteria

Patients who are candidates for receive systemic corticosteroids
Patients who are not volunteer to receive intratympanic corticosteroids

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hearing improvement based on audiometry. Timepoint: Complete response to treatment refers to an increase of 30 dB after 15 to 45 days after IT injection of dexamethasone and triamcinolone. The relative response to treatment refers to an increase of 10 dB 15 to 45 days after IT injection of dexamethasone. An improvement of less than 10 decibels will be considered as no response or failure of treatment. Method of measurement: Based on audiometry.